Pharmaceutical application of 1-(4-alkynyl-2-deoxy-2-fluoro-beta-D-ribofuranosyl) cytosine or salt thereof
The existing nucleoside drugs in anti-tumor treatment have been resolved by developing 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine (CL-351) or its salts The problems of limited activity and great toxic and side effects have achieved efficient inhibition and low toxicity on a variety of tumors, significantly prolonging the survival of leukemia mice, and playing a role by inhibiting the PI3K/AKT/mTOR signaling pathway.
Patent Information
- Application Number
- CN202411196971.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-29
AI Technical Summary
Existing nucleoside drugs have limited activity in anti-tumor treatment, are prone to inactivate and have serious toxic side effects, and are prone to drug resistance, making it difficult to develop new anti-activity, few toxic side effects, and are not prone to drug resistance. Tumor drugs.
1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine (CL-351) or its salt was developed. Through improved synthesis technology and a large number of activity screening tests, it was found that it had It has good anti-tumor activity and can be used to prepare a variety of tumor drugs, including leukemia, lymphoma, pancreatic cancer, etc., which plays a role by inhibiting the PI3K/AKT/mTOR signaling pathway.
CL-351 has a proliferation inhibitory effect on a variety of tumor cells, mainly blocking the leukemia cell cycle in the S phase, inducing tumor cell apoptosis, significantly prolonging the survival of leukemia mice, significantly inhibiting tumor cell proliferation and spleen tissue infiltration in vivo, and The characteristics of high efficiency and low toxicity reduce the occurrence of drug resistance.
Smart Images

Figure CN119033801A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the application of nucleoside analogs, in particular to the pharmaceutical application of 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine (CL-351) or its salt, belonging to the field of pharmaceutical chemistry. Background Art
[0002] Nucleoside compounds have been shown to have the potential to treat various human diseases, and have good activity against viral infections and tumor treatment, and have become a hot topic of research at home and abroad. After nucleoside analogs form active metabolites through three-step phosphorylation, they participate in regulating various cellular biological processes such as DNA and RNA synthesis, enzyme regulation, metabolism, and cell signal transduction, and ultimately exert anti-tumor effects. In terms of tumor treatment, although many nucleoside drugs have been listed on the market, these drugs have not yet achieved ideal therapeutic effects in anti-tumor treatment. On the one hand, the drug activity is limited and it is easy to be inactivated during the metabolic process. On the other hand, long-term use has serious toxic side effects and it is difficult to avoid the occurrence of drug resistance. Therefore, the research and development of new nucleoside analogs is still an important research direction. The inventor has been engaged in the relevant research of nucleoside analogs for a long time, and applied for the invention patent "2'-Fluoro-4'-Substituted Nucleoside Analogs, Preparation Methods and Applications Thereof" (ZL200710137548.0) in August 2007. It has been authorized. This type of compound has been confirmed to have antiviral effects. Further research has also found that this type of compound not only has antiviral activity, but also has good anti-tumor activity. Currently, there are many kinds of drugs for treating tumors, but most of them have the disadvantages of large toxic side effects and are easy to cause drug resistance in patients. Therefore, there is an urgent need to find and develop new anti-tumor drugs with high activity, low toxic side effects and not easy to cause drug resistance in patients. Summary of the invention
[0003] Based on the current state of the art, the present invention aims to provide a pharmaceutical application of 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine (CL-351) or a salt thereof, which is conducive to the development of anti-tumor drugs with high activity, low toxicity and side effects, and not easy to cause drug resistance in patients.
[0004] To achieve the purpose of the present invention, the researchers of the present invention further improved the synthesis process based on the patent "2'-Fluoro-4'-substituted nucleoside analogs, preparation methods and applications thereof" (ZL200710137548.0); a large number of activity screening tests were conducted on such compounds, and it was found that 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine (CL-351) has good anti-tumor activity and can be used in the preparation of anti-tumor drugs.
[0005] The 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine has the following molecular structural formula:
[0006] ESI-MS of this compound: 270.09[M+H] + , Properties: Light yellow solid, melting point 141-145°C. Referred to as CL-351.
[0007] The compound or its 5'-phosphate ester can react with an organic acid or an inorganic acid to form a salt and exist in the form of a salt.
[0008] The application of the nucleoside analogue CL-351 or its salt in the preparation of anti-tumor drugs is applied to the preparation of drugs for treating leukemia, lymphoma, pancreatic cancer, lung cancer, gastric cancer, liver cancer, breast cancer and other tumors. The preliminary in vitro and in vivo animal test results show that CL-351 has a proliferation inhibitory effect on various tumor cells such as leukemia and lymphoma. Under the same conditions, the anti-tumor effect of CL-351 is better than that of cytarabine. CL-351 of the present invention is a new type of anti-tumor drug with high efficiency and low toxicity. CL-351 has good water solubility and can be made into an injection or an oral administration dosage form. The dosage forms include: intravenous small water injection, large infusion, freeze-dried powder injection, tablets, capsules (ordinary capsules, microcapsules, soft capsules), drip pills, sustained-release preparations and nano preparations.
[0009] The nucleoside analog CL-351 or its salt of the present invention is used as an active ingredient, mixed or combined with medically acceptable pharmaceutical excipients, vehicles, etc. to prepare the above-mentioned various dosage forms; it can also be used together with other anti-tumor drugs as active ingredients, mixed or combined with medically acceptable pharmaceutical excipients, vehicles, etc. to prepare the above-mentioned various dosage forms.
[0010] Small water injection for intravenous use: 100g of the nucleoside analog CL-351 of the present invention or its salt is mixed with sodium bicarbonate, benzyl alcohol, sodium bisulfite and water for injection in a mass volume ratio of 1:4, and then sterilized and packaged into injections to prepare injections. Specification: 3mg / 2ml. Intended clinical dosage: 6mg / day, twice / day.
[0011] Large infusion: 12 mg of the nucleoside analogue CL-351 or its salt of the present invention is mixed with water for injection at a ratio of 4.8 mg:100 ml, and then 0.15% activated carbon is added for decolorization, filtered until clear, filled and sealed to make a large infusion, and sterilized by hot pressure. Specification: 12 mg / 250 ml, clinical dosage: 12 mg / day.
[0012] Freeze-dried powder for injection: 100 mg of the nucleoside analog CL-351 or its salt of the present invention is dissolved in water for injection with hydrolyzed gelatin, mannitol, calcium gluconate, cysteine, etc., sterile filtered, and dispensed into ampoules, 10 ml each, freeze-dried and sealed, dissolved with sodium chloride injection or 5% glucose injection before use and dripped. Specification: 100 mg (content 12 mg). Intended clinical dosage: 12 mg / day.
[0013] Tablets: The nucleoside analog CL-351 or its salt of the present invention is mixed with diluents and lubricants such as microcrystalline cellulose, lactose, magnesium stearate, etc., and is pressed into tablets by standard concave punching according to known tableting techniques and equipment to prepare tablets. Specification: 0.1 g / tablet (content 10 mg / tablet). Intended clinical dosage: 20 mg / day, twice / day.
[0014] Capsules (regular capsules, soft capsules, micro capsules):
[0015] Ordinary capsules: Mix the nucleoside analog CL-351 or its salt powder with magnesium stearate and the like at a mass ratio of 1:9, and fill into empty capsules to obtain the product. Specification: 0.1 g / capsule (content 10 mg / capsule). Intended clinical dosage: 20 mg / day, twice / day.
[0016] Soft capsule: heat and melt the nucleoside analogue CL-351 of the present invention or its saline solution with glycerol, water and gelatin, mix them evenly, add them into a dripping pill machine and drip them to obtain the soft capsule. Specification: 10 mg / pill (content 5 mg / pill), clinical dosage: 20 mg / day, twice / day.
[0017] Microcapsules: The nucleoside analogue CL-351 or its salt powder of the present invention is dispersed in gelatin material, and sodium sulfate aqueous solution is added, and PEG formaldehyde is condensed into capsules by single condensation method. Specification: 0.2 mg / capsule (content 0.1 mg / capsule), clinical dosage: 20 mg / day, twice / day.
[0018] Dropping pills: 1 part of the nucleoside analog CL-351 or its salt of the present invention is mixed with 9 parts of PEG6000 at a mass ratio of 1:9, and prepared into dropping pills by solid dispersion technology. Specification: 10 mg / pill (content 5 mg / pill), clinical dosage: 20 mg / day, twice / day.
[0019] Sustained-release preparation: Mix the nucleoside analogue CL-351 or its salt with hydroxymethylcellulose, dissolve sodium citrate in ethanol as a wetting agent to make a soft material, granulate, dry, granulate, add stearic acid and lactose, mix, and press into tablets. Specification: 0.3g / tablet (content 60mg / tablet), clinical dosage: 60mg / 3 days.
[0020] Nano preparation: The nucleoside analogue CL-351 or its salt of the present invention is mixed with phospholipids, an emulsifier and water by nanoemulsification to prepare a nanoemulsion or submicroemulsion, and then poured into ice water for cooling to obtain nanoparticles or submicroemulsion. Specification: 12mg / 2ml, clinical dosage: 12mg / day.
[0021] The new preparation process of CL-351 of the present invention is as follows:
[0022] Specifically through the following steps:
[0023] Synthesis of compound 2: Compound 1 (150.0 g, 0.323 mol) was added with hydrobromic acid-acetic acid solution (45%, v / v, 300 mL) in an ice-water bath, stirred at room temperature for 16 h, and 1 L of water was added after complete reaction. Compound 2 was obtained after organic phase extraction and vacuum rotary evaporation. MS (ESI) m / z: C 19 H 16 BrFO5[M+H] + Theoretical value 423.02, actual measured value 423.11.
[0024] Synthesis of compound 5: Compound 3 (47.3 g, 0.422 mol) and 450 mg of (NH4)2SO4 were added to hexamethyldisilazane (270 mL, 202.5 g), refluxed for 16 h, and excess hexamethyldisilazane was distilled off. A chloroform solution of compound 2 (900 mL) was added, and the reflux reaction was continued for 24 h. After the reaction was completed, ice water was added and stirred overnight. Extracted with dichloromethane, washed with saturated sodium bicarbonate solution, and dried over anhydrous sodium sulfate. After filtration, the filtrate was distilled under reduced pressure to obtain compound 5. MS (ESI) m / z: C 23 H 19 FN2O7[M+H] + Theoretical value is 455.12, actual measured value is 455.19.
[0025] Synthesis of compound 6: Compound 5 (100 g, 0.220 mol) was added to 2.5 L of saturated methanol-ammonia solution at room temperature and stirred at room temperature for 24 h. After the reaction was completed, the solvent was removed by distillation under reduced pressure, and the residue was washed with dichloromethane and filtered to obtain compound 6. MS (ESI) m / z: C9H 11 FN2O5[M+H] + Theoretical value is 247.07, actual measured value is 247.18. 1H NMR (300MHz, DMSO-d6) δ11.35(brs,1H),7.71(dd,J=8.05,1.46Hz,1H),6.10(dd,J=16.10,4.39Hz,1H),5.87(d,J=5.12Hz,1H),5.64(d, J=8.05Hz,1H),5.08(t,J=5.85Hz,1H),5.03(ddd,J=52.69,4.03,2.93Hz,1H),4.21(dm,J=19.76Hz,1H),3.79(m,1H),3.60(m,2H)ppm.
[0026] Synthesis of compound 7: Compound 6 (42.3 g, 0.172 mol) and imidazole (40.96 g, 0.602 mol) were dissolved in N, N-dimethylformamide (800 mL). Under argon protection at 0°C, tert-butyldimethylsilyl chloride (77.76 g, 0.516 mol) was added while stirring the solution. The resulting mixture was heated to 25°C and stirred for 2 h. The resulting solution was diluted with water and extracted with ethyl acetate several times. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was distilled under reduced pressure. The resulting solid was separated by column chromatography gradient elution to obtain compound 7. MS (ESI) m / z: C 21 H 39 FN2O5Si2[M+H] + Theoretical value is 475.25, actual measured value is 475.33.
[0027] Synthesis of compound 8: At 0°C, slowly inject compound 7 (63.7 g, 0.134 mol) dissolved in 1.28 L tetrahydrofuran solution into a pre-cooled trifluoroacetic acid / water (640 mL, v / v, 1 / 1) solution. Stir at low temperature for 1.5 h until the reaction is complete. The resulting solution and toluene are rotary evaporated at low temperature below 25°C, and the residue is redissolved in methanol / dichloromethane (1.6 L, v / v, 1 / 2) and neutralized with saturated sodium bicarbonate solution. After filtration, the filtrate is concentrated by rotary evaporation under reduced pressure, and the solid is separated by column chromatography gradient elution to obtain compound 8. MS (ESI) m / z: C 15 H 25 FN2O5Si[M+H] + Theoretical value is 361.16, actual measured value is 361.24.
[0028] Synthesis of compound 9: Under argon protection at room temperature, 2-iodobenzoic acid (72 g, 0.257 mol) was added to a suspension of compound 8 (31.0 g, 0.0860 mol) in anhydrous acetonitrile (3.6 L) while stirring, and the resulting mixture was heated to 80°C and stirred for 1 h. The solid was filtered out and the filtrate was evaporated under reduced pressure to obtain compound 9, which was directly used in the next reaction without further purification.
[0029] Synthesis of compound 10: Compound 9 (27.9 g, 0.0778 mol) was dissolved in 1,4-dioxane (2.0 L), and a 37% aqueous solution of formaldehyde (400 mL) was added under stirring. After reacting at room temperature for 5 minutes, an aqueous sodium hydroxide solution (400 mL, 2 M) was injected, and the resulting mixture was stirred at room temperature for 5 h. When all the raw materials reacted, the reaction mixture was neutralized with an appropriate amount of acetic acid. The resulting mixture was diluted with ethyl acetate and washed with water, saturated sodium bicarbonate aqueous solution and saturated brine in sequence. The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The residue was redissolved in anhydrous ethanol and sodium borohydride (5.8 g, 153.6 mmol) was added in batches at 0°C under argon protection. Stir at room temperature for 16 h, neutralize the reaction mixture with acetic acid and evaporate under reduced pressure. After chloroform extraction, it was dried over anhydrous sodium sulfate, filtered and the filtrate was evaporated under reduced pressure. The resulting solid was separated by column chromatography gradient elution to obtain compound 10. MS (ESI) m / z: C 16 H 27 FN2O6Si[M+H] + Theoretical value is 391.17, actual measured value is 391.27. 1 H NMR (300MHz, CD3OD) δ8.02(d,J=8.05Hz,1H),6.44(dd,J=7.68,5.85Hz,1H),5.70(d,J=8.05Hz,1H),5.35( dt,J=55.99,5.49Hz,1H),4.67(dd,J=25.61,5.49Hz,1H),3.41-3.78(m,4H),0.94(s,9H),0.15(s,6H)ppm.
[0030] Synthesis of compound 11: Compound 10 (15.6 g, 0.0400 mol) was dissolved in ACN / DMSO (680 mL, v / v, 10 / 1), 2-iodobenzoic acid (33.6 g, 0.120 mol) was slowly added to the suspension under argon protection at room temperature, stirred at 30°C until the reaction was complete, and the solid was filtered out. The filtrate was evaporated under reduced pressure to obtain compound 11, which was directly used in the next reaction step without further purification.
[0031] Synthesis of compound 12: Compound 11 (14.0 g, 0.0360 mol) was dissolved in anhydrous methanol (450 mL). Potassium carbonate (14.9 g, 108.1 mmol) was added under stirring at room temperature under argon protection, and then a methanol (112 mL) solution containing (1-diazo-2-oxopropyl)phosphonic acid dimethyl ester (13.8 g, 72.1 mmol) was slowly added at 0°C. The mixture was stirred at 25°C until the reaction was complete and then evaporated under reduced pressure. The residue was separated by column chromatography gradient elution to obtain compound 12. MS (ESI) m / z: C 17 H 25 FN2O5Si[M+H] + Theoretical value is 385.16, actual measured value is 365.25.
[0032] Synthesis of compound 13: Compound 12 (7.69 g, 0.0200 mol) was dissolved in dichloromethane (250 mL), imidazole (4.06 g, 60.0 mmol) and tert-butyldiphenylsilyl chloride (8.2 g, 30.0 mmol) were added, and the mixture was stirred at room temperature for about 3 h. After the reaction was completed, extraction and vacuum distillation were performed to obtain compound 13. MS (ESI) m / z: C 33 H 43 FN2O5Si2[M+H] + Theoretical value is 623.28, actual measured value is 623.36. 1 H NMR (300MHz, CDCl3) δ10.14(s,1H),7.62-7.70(m,4H),7.39-7.47(m,7H),6.46(dd,J=11.71,5.49Hz,1H),5.41(d,J=8.05Hz,1H),5.18(dt .
[0033] Synthesis of compound 14: Compound 13 (12.0 g, 0.0193 mol) was dissolved in dichloromethane (600 mL) and 1,2,4-triazole (14.64 g, 211.8 mmol) and pyridine (17.1 mL, 211.8 mmol) were added. Phosphorus oxychloride (10.0 mL, 96.3 mmol) was added under stirring at 0°C, and the reaction was continued under stirring at low temperature for 2 h, and then the reaction was stirred at room temperature for about 12 h. Water was added to terminate the reaction, and the solvent was evaporated after extraction with dichloromethane. The residue was dissolved in tetrahydrofuran (900 mL), and a saturated aqueous ammonia solution (33%, 900 mL) was added. After stirring at room temperature for 1 h, the solvent was evaporated, and the residue was separated by column chromatography gradient elution to obtain compound 14. MS (ESI) m / z: C 33 H 44 FN3O4Si2[M+H] + Theoretical value is 622.29, actual measured value is 622.40. 1 H NMR (300MHz, CDCl3) δ7.64-7.70(m,4H),7.53(dd,J=7.32,1.10Hz,1H),7.37-7.45(m,6H),6.50(dd,J=13.76,4.76Hz,1H),5.43(d,J=7.32Hz,1H),5.1 7(ddd,J=53.79,4.76,3.66Hz,1H),4.72(ddd,J=23.42,3.66Hz,1H),3.89(m ,2H),2.51(s,1H),1.10(s,9H),0.91(s,9H),0.14(s,3H),0.12(s,3H)ppm.
[0034] Synthesis of compound CL-351: Compound 14 (10.6 g, 0.017 mol) was dissolved in methanol (450 mL), and ammonium fluoride (12.59 g, 340.3 mmol) was added, and the mixture was refluxed for 5 h. The residue after evaporation of the solvent was separated by column chromatography gradient elution to obtain compound CL-351 (4.17 g, off-white powdery solid), with a melting point of 141-145 ° C and a HPLC purity of more than 98%. HRMS (ESI) m / z: C 11 H 12 FN3O4[M+H] + Theoretical value is 270.08846, actual measured value is 270.08814. 1H NMR (400MHz, CD3OD) δ7.80 (dd, J=7.6, 1.2Hz, 1H), 6.36 (dd, J=11.8, 5.3Hz, 1H), 5.90 (d, J=7.5Hz, 1H), 5.19 (dt, J=5 4.1,5.0Hz,1H),4.45(dd,J=24.5,4.8Hz,1H),3.86(dd,J=12.4,1.7Hz,1H),3.75(d,J=12.4Hz,1H),3.18(s,1H)ppm; 13 C NMR(101MHz,CD3OD)δ167.7,157.9,143.3(d,J C-F =1.8Hz),97.0(d,J C-F =192.3Hz),95.8,83.8(d,J C-F =17.3Hz),82.0(d,J C-F =8.3Hz),79.8,79.6,75.3(d,J C-F =25.3Hz),64.3ppm; 19 FNMR (376MHz, CD3OD) δ-200.7ppm..
[0035] The advantages of the present invention are as follows: further studies have found that 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine (CL-351) or its salt has good anti-tumor activity, which is reflected in the following aspects: (1) CL-351 has a proliferation inhibitory effect on various tumor cells such as leukemia and lymphoma. (2) CL-351 mainly blocks the leukemia cell cycle at the S phase and induces tumor cell apoptosis. (3) CL-351 can significantly prolong the survival of leukemia mice and significantly inhibit the proliferation of tumor cells and spleen tissue infiltration in vivo, showing good anti-leukemia activity. (4) CL-351 can exert an anti-leukemia effect by inhibiting the phosphorylation of key proteins in the PI3K / AKT / mTOR signaling pathway. The development of this type of drug lays a foundation for the research of fluorinated nucleoside analogs, and is of great significance to the development of drugs with independent intellectual property rights in my country. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 The effect of CL-351 of the present invention on the cell cycle distribution of Jurkat (A) and Molt-4 (B) (n=3) (compared with the negative control group, *p<0.05, **p<0.01, ***p<0.001); Figure 2 The effect of CL-351 of the present invention on the cell cycle distribution of CEM / C1 (A) and CCRF-CEM (B) (n=3) (compared with the negative control group, *p<0.05, ** p<0.01, *** p<0.001); Figure 3 The effect of CL-351 of the present invention on apoptosis of Jurkat (A), Molt-4 (B), CEM / C1 (C) and CCRF-CEM (D) cells (flow cytometry apoptosis graph and statistical graph), (n=3) (compared with the negative control group, * p<0.05, ** p<0.01, *** p<0.001); Figure 4 The effect of CL-351 of the present invention on apoptosis of Jurkat (A), Molt-4 (B), CEM / C1 (C) and CCRF-CEM (D) cells (fluorescence staining apoptosis graph and statistical graph (40×), (n=3) (compared with the negative control group, * p<0.05, ** p<0.01, *** p<0.001); Figure 5 The effect of CL-351 of the present invention on the expression of apoptosis-related proteins in Jurkat (A) and Molt-4 (B) cells (n=3) (compared with the negative control group, * p<0.05, ** p<0.01, *** p<0.001); Figure 6 The effect of CL-351 of the present invention on the survival of leukemia mice (n=5) (compared with the negative control group, * p<0.05, ** p<0.01, *** p<0.001); Figure 7 The effect of CL-351 on the number of WBC and Neu ratio in leukemia mice (n=5) (compared with the negative control group, * p<0.05, ** p<0.01, *** p<0.001); Figure 8 The effect of CL-351 of the present invention on the proliferation of leukemia cells in leukemia mice, wherein Figure A: blood smear (200×); Figure B: bone marrow smear (400×); Figure C: species gene ratio; Figure D: flow cytometry detection; (n=5) (compared with the negative control group, * p<0.05, ** p<0.01, *** p<0.001); Fig. 9 The effect of CL-351 of the present invention on spleen infiltration in leukemia mice, wherein Figure A: mouse tissue picture; Figure B: mouse spleen tissue and liver tissue weight; Figure C: mouse spleen tissue HE staining (200×); Figure D: mouse spleen tissue CD45 immunohistochemistry (400×); (n=5) (compared with the negative control group, * p<0.05, ** p<0.01, *** p<0.001); Fig.10 This is the GO enrichment analysis of differentially expressed genes in Molt-4 cells by CL-351 of the present invention; Fig.11 KEGG enrichment analysis of differentially expressed genes in Molt-4 cells by CL-351 of the present invention; Fig.12 The effect of CL-351 of the present invention on the expression of proteins related to the PI3K / AKT / mTOR signaling pathway in Jurkat (A) and Molt-4 (B) cells (n=3) (compared with the negative control group, * p<0.05, ** p<0.01, *** p<0.001); Fig.13 The H NMR spectrum of the intermediate product 6 in the preparation process of CL-351 of the present invention is 1 H NMR; Fig.14 The H NMR spectrum of the intermediate product 10 in the preparation process of CL-351 of the present invention is 1 H NMR; Fig.15 The H NMR spectrum of the intermediate product 13 in the preparation process of CL-351 of the present invention is 1 H NMR; Fig.16 The H NMR spectrum of the intermediate compound 14 in the preparation process of CL-351 of the present invention is 1 H NMR; Fig.17 The nuclear magnetic hydrogen spectrum of CL-351 of the present invention is 1 H NMR; Fig.18 The NMR carbon spectrum of CL-351 of the present invention is 13 C NMR; Fig.19 The nuclear magnetic fluorine spectrum of CL-351 of the present invention is 19 F NMR; Fig. 20 is a high-resolution mass spectrum of the CL-351 compound of the present invention; Fig.21 It is the high performance liquid chromatography spectrum of the CL-351 compound of the present invention. DETAILED DESCRIPTION
[0036] In order to better illustrate the present invention, the following experiment was used to verify the anti-tumor activity of CL-351 of the present invention. Unless otherwise specified, the following percentages are all weight percentages. 1 Experimental Materials 1.1 Cell lines Human acute T lymphoblastic leukemia cells Jurkat, Molt-4, CCRF-CEM and CEM / C1 cells. Human Burkitt lymphoma cells Raji and Daudi, human diffuse tissue lymphoma cells SU-DHL-4, human acute promyelocytic leukemia cells HL-60, human acute myeloid leukemia cells MOLM-13, human myelomonocytic leukemia MV4-11, human monocytic leukemia THP-1, human pancreatic cancer cells Miapaca-2, human lung cancer cells A549, human gastric cancer cells SGC-7901, human liver cancer cells HepG2, human breast cancer cells MDA-MB-231. 1.2 Experimental animals SPF NOD-Prkdc scid IL tm1 Mice (NSIG), female, 14-16g, were purchased from Beijing Huafukang Biotechnology Co., Ltd. (certificate number: NO.110322231103705823; license number: SCXK (Beijing) 2018-0008) and were raised in IVC isolation cages in the SPF-level Animal Center of Henan Academy of Medical Sciences (license number: SCXK (Yu) 2021-0017). The experiment was approved by the Animal Ethics Committee of Henan Academy of Medical Sciences. 1.3 Preparation of 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine (CL-351) solution 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine (CL-351), off-white powder, purity greater than 98%, relative molecular mass of 269, provided by the School of Pharmacy of Zhengzhou University. Use a 1.5mL EP tube to accurately weigh 5.0mg of CL-351 powder (stored in this laboratory), add the DMSO required for the preparation of 50mM stock solution into the EP tube, fully dissolve, and store at -20℃ to avoid repeated freezing and thawing. 2 Experimental methods 2.1 MTT assay to detect the anti-pancreatic cancer, lung cancer, gastric cancer, liver cancer, and breast cancer activity of CL351 (1) Collect pancreatic cancer, lung cancer, gastric cancer, liver cancer, and breast cancer cells in logarithmic growth phase, centrifuge at 1000 rpm for 3 min, and discard the supernatant. Pipette fresh culture medium to resuspend the cells and count them, adjust the cell density to 4000 cells / well, evenly add 100 μL per well of a 96-well plate, and culture overnight in an incubator. (2) After discarding the original culture medium in each well, add 100 μL of CL-351 drug solution to each well, with final concentrations of 6.25, 12.50, 25.00, 50.00, and 100.00 μmol / L. Add the same volume of drug-free culture medium to the negative control group. Set up 3 to 5 replicate wells for each concentration and continue culturing in the incubator. (3) After culturing for 72 h, 20 μL of MTT was added and the cells were incubated for another 4 h. Finally, 150 μL of DMSO was added to dissolve the formazan crystals and the cells were placed on a shaker at room temperature in the dark for 15 min. (4) After incubation, remove the culture plate and use an automatic enzyme-linked immunosorbent analyzer to measure the absorbance value (OD value) of each well at a wavelength of 490 nm. Repeat the experiment three times. (5) SPSS 21.0 software was used to perform statistical analysis on the data and calculate the IC50 value. 2.2 Detection of anti-lymphoma and leukemia activity of CL351 by CCK8 assay (1) Collect lymphoma and leukemia cells growing in the logarithmic phase, centrifuge at 1000 rpm for 5 min, and discard the supernatant. Pipette fresh medium to resuspend the cells and count them, adjusting the cell density to 8×10 3 Add evenly into 96-well plate, 100 μL per well. (2) Add 50 μL of CL-351 drug solution to each well, with final concentrations of 6.25, 12.50, 25.00, 50.00, and 100.00 nmol / L. Add the same volume of drug-free culture medium to the negative control group. Set up 3-5 replicate wells for each concentration and continue culturing in an incubator. (3) After culturing for 72 h, 10 μL of CCK8 solution was added to each well, and the culture plate was placed in an incubator and incubated for 2 h. (4) After the incubation, the culture plate was removed and the absorbance value (OD value) of each well was measured at a wavelength of 450 nm using an automatic enzyme-linked immunosorbent assay. The experiment was repeated three times. (5) SPSS 21.0 software was used to perform statistical analysis on the data and calculate the 50% inhibitory concentration (IC50). 2.3 AnnexinⅤ-FITC / PI double staining method to detect the effect of CL-351 on leukemia cell apoptosis (1) Jurkat, Molt-4, CCRF-CEM and CEM / C1 cells were collected and plated at 1×10 6 pc / mL were evenly spread on a 6-well plate. (2) A certain concentration of CL-351 drug solution was added so that the final concentrations in the Jurkat, Molt-4, and CEM / C1 cell suspensions were 10.00, 20.00, and 40.00 nM, respectively, and the final concentrations in the CCRF-CEM cell suspensions were 6.25, 12.50, and 25.00 nM, respectively. The same volume of medium without the drug was added to the negative control group and the cells were placed in an incubator for continued culture. (3) After incubation, wash the cells twice. (4) Resuspend the cells in 500 μL Binding Buffer. (5) Add 5 μL Annexin V-FITC and 5 μL Propidium Iodide, mix well, and incubate at room temperature in the dark for 5 min. (6) Flow cytometry was used for detection. 2.4AO / EB detection of the effect of CL-351 on leukemia cell apoptosis (1) Jurkat, Molt-4, CCRF-CEM and CEM / C1 cells were collected and cultured at 1×10 6 pc / mL were evenly spread on a 6-well plate. (2) A certain concentration of CL-351 drug solution was added so that the final concentrations in the Jurkat, Molt-4, and CEM / C1 cell suspensions were 10.00, 20.00, and 40.00 nM, respectively, and the final concentrations in the CCRF-CEM cell suspensions were 6.25, 12.50, and 25.00 nM, respectively. The same volume of medium without the drug was added to the negative control group and the cells were placed in an incubator for continued culture. (3) After 48 hours, the cell culture 6-well plate was taken out and the cell pellet was collected and washed. (4) Add AO / EB working solution to cells in each experimental group. (5) Evenly add 10 μL of cell suspension onto each glass slide. (6) Take photos and record using a fluorescence microscope. 2.5 Detection of leukemia cell cycle by propidium iodide (PI) single staining (1) Jurkat, Molt-4, CCRF-CEM and CEM / C1 cells were collected and cultured at 1×10 6 pc / mL were evenly spread on a 6-well plate. (2) A certain concentration of CL-351 drug solution was added to make the final concentrations in the Jurkat, Molt-4, and CEM / C1 cell suspensions 10.00, 20.00, and 40.00 nM, respectively, and the final concentrations in the CCRF-CEM cell suspensions 6.25, 12.50, and 25.00 nM, respectively. The same volume of medium without the drug was added to the negative control group and the cells were placed in an incubator for continued culture. (3) After 48 hours, the cell culture 6-well plate was taken out and the cell pellet was collected and washed. (4) Fix the cells with 70% ethanol solution at 4°C overnight. (5) After washing the cell pellet, the cells were collected by centrifugation. (6) Add PI / RNase A working solution and incubate at room temperature in the dark for 30 min. (7) Flow cytometry was used for detection. 2.6 Western Blot detection of the effect of CL-351 on the expression of apoptosis-related proteins in Jurkat and Molt-4 cells (1) Jurkat, Molt-4, CCRF-CEM and CEM / C1 cells were collected and cultured at 1×10 6 pc / mL were evenly spread on a 6-well plate. (2) Specific concentrations of CL-351 solution were added to each experimental group, so that the final concentrations in the Jurkat and Molt-4 cell suspensions were 10.00, 20.00, and 40.00 nM, respectively. The same volume of medium without drug was added to the negative control group and the cells were placed in an incubator for continued culture. (3) After 48 h, collect the cells and transfer them to an ice box. (4) Each cell sample was added with 300 μL of the lysis buffer prepared in advance and lysed on ice for 0.5 h. (5) After lysis, centrifuge at 4°C and collect the supernatant. (6) The concentration of the protein sample was measured by Thermo Nano Drop 2000 UV spectrophotometer. After dilution, 1 / 4 of the protein sample was added to 5× SDS loading buffer and boiled for denaturation. (7) Preparation of separation gel: Add each reagent according to the instructions to prepare the required separation gel, and quickly use a 1mL pipette to slowly add 7.5mL of the prepared separation gel to the glass plate, taking care to avoid bubbles. Use ultrapure water for liquid sealing and leave it at room temperature for 30 minutes to wait for it to solidify. Preparation of concentrated gel: After the separation gel is completely solidified, add each reagent according to the instructions to prepare the required concentrated gel, and quickly use a 1mL pipette to slowly add 4mL of the prepared concentrated gel to the upper layer of the separation gel. Quickly insert a 10mm comb into the concentrated gel and leave it at room temperature for 20 minutes to wait for it to solidify. (8) Sample loading and electrophoresis: Pour enough 1× electrophoresis buffer into the electrophoresis tank and carefully pull out the comb. Observe whether there are bubbles in the sample loading well. If there are bubbles, use a syringe to drive them out and then add the sample. Be careful not to damage the lanes. Take the collected samples out of the refrigerator in advance, dissolve them completely and mix them thoroughly, then add a certain amount of sample to each well and add 5μL of protein marker to each lane on both sides. After the sample loading is completed, adjust the voltage and start electrophoresis. After the electrophoresis is completed, turn off the power supply. (9) Transfer: In a large culture dish, use enough 1× rapid transfer solution to fully soak the sponge pad, filter paper, etc., and completely remove the bubbles in them to make a "sandwich" structure. In a small culture dish, use an appropriate amount of methanol solution to soak and activate the PVDF membrane. Cut the target protein strip according to the protein marker and transfer it to the transfer solution for soaking. After placing the target gel strip taken out of the transfer solution on the filter paper of the transfer clamp, place the PVDF membrane on the target gel strip and carefully cover the filter paper. During this period, be sure to completely remove the bubbles. Start the transfer in an ice water bath. (10) Blocking and immune response: Place the PVDF membrane in the blocking solution prepared in advance and incubate with shaking for 4 hours. Place the PVDF membrane in the primary antibody prepared in advance and incubate overnight in a 4°C refrigerator. After incubation, wash the PVDF membrane with TBST and place it in the secondary antibody prepared in advance and incubate with shaking for 1 hour. After the secondary antibody incubation is completed, wash the PVDF membrane with TBST. (11) ECL chemiluminescence color development: drop the prepared ECL chemiluminescence solution on the PVDF membrane, place it in the machine for exposure, and image. Use Image J to analyze the gray value of the protein band. 2.7 Establishment of leukemia xenograft model and drug administration (1) Cell collection: Molt-4 cells in the logarithmic growth phase and in good condition were collected, washed once with pre-cooled RPMI-1640 medium, and the cell density was adjusted to 5×10 7 / mL and place on ice for later use. (2) Inoculation: Before inoculation, the tail of the NSIG mouse was disinfected with 75% alcohol. After the cell suspension was mixed, 0.2 mL of the cell suspension was injected into the tail vein of each mouse. (3) Grouping: NSIG mice were randomly divided into four groups, namely, model group, CL-351 low-dose group, CL-351 medium-dose group, and CL-351 high-dose group, with 10 mice in each group, of which 5 were used for survival study and 5 were used for in vivo efficacy study. (4) Administration: On the second day after inoculation, administration began. The low, medium, and high dose groups of CL-351 were administered by gavage at doses of 0.125, 0.25, and 0.5 mg / kg, respectively, twice a week; the model group was given normal saline in the same manner, and each group of mice was administered at a volume of 0.2 mL / 10 g. (5) Observation: Observe the changes in the food intake, water intake, and mental state of each group of mice every day. When the mice lose weight and become paralyzed in their hind limbs, it indicates that the disease has progressed to a more serious stage. (6) 21 days after the inoculation of Molt-4 cells in some mice, the mice in each group used for in vivo efficacy study were anesthetized and blood was collected. The spleen, liver, kidney, and bone marrow tissues were dissected and weighed. The spleen and liver were photographed. Each tissue was fixed with 4% paraformaldehyde fixative for pathological examination. The remaining mice were given normal medication until death to investigate the effect of CL-351 on the survival of leukemia mice. 2.8 Collection of whole blood samples from animals (1) Whole blood of mice was collected by eye removal into a 1.5 mL EP tube containing anticoagulant. When all the blood was drained, the mice were killed. (2) Add red blood cell lysis buffer to a 1.5 mL EP tube, mix well, and place on ice for 15 min. Mix well and collect cells. Repeat this process 3-4 times until the solution is clear and transparent. (3) Add TriZol lysis buffer and repeatedly pipette until fully lysed. (4) Transfer to a -192°C cryotube and store at -80°C. 2.9 Animal Bone Marrow Sample Collection (1) After killing the mice, separate the femurs of the mice and place them in a cell culture dish. Remove the muscles and fibrous tissues on the bones. (2) Disconnect the two ends of the femur and make sure both ends are clean. Use a 10 mL syringe to aspirate 5 mL of culture medium and carefully flush out the bone marrow. (3) Add red blood cell lysis buffer to a 1.5 mL EP tube, mix well, and place on ice for 15 min. Mix well and collect cells. Repeat this process 3-4 times until the solution is clear and transparent. (4) Add TriZol lysis buffer and repeatedly pipette until fully lysed. (5) Transfer to a -192°C cryotube and store at -80°C. 2.10 Analysis of five types of blood cells in leukemia mice The whole blood of each group of mice was collected into a 1.5 mL EP tube containing an anticoagulant by removing the eyeball. When the blood was drained out, the mice were killed by dislocation. The blood samples were commissioned to Wuhan Saiweier Biotechnology Co., Ltd. for five-category blood cell analysis. 2.11 Analysis of differences in gene matching rates between whole blood and bone marrow After using Cutadapt to filter out unqualified sequences such as sequencing adapters and low-quality sequences in the original data to obtain valid data, Hangzhou Lianchuan Biotechnology Co., Ltd. was commissioned to use human and mouse databases to compare the whole blood and bone marrow reference genomes. 2.12 Wright-Giemsa staining to detect the efficacy of CL-351 in the treatment of leukemia in vivo (1) Take 10 μL of whole blood or bone marrow and apply it evenly on the fragment. (2) After the slide is dried, place it in methanol solution for fixation for 5 minutes. (3) Mix Wright-Giemsa staining solution and phosphate buffered saline in a 1:1 ratio. (4) Add the above mixed solution dropwise onto the peripheral blood and bone marrow smears until the glass smears are completely covered by the dye solution. Stain for 5 minutes. (5) Wash with water. Do not pour out the staining solution first when washing. Wash slowly from one end of the slide to prevent sediment from settling on the specimen. Dry and examine under a microscope. 2.13 Flow cytometry to detect the efficacy of CL-351 in the treatment of leukemia in vivo (1) Add 3 volumes of red blood cell lysis buffer to fresh whole blood or bone marrow and gently vortex or invert to mix. (2) Place on ice for 15 min. Gently vortex twice to mix. Repeat 2-4 times until the solution is clear and transparent, indicating that the red blood cells have been fully lysed. (3) Wash the cells once with PBS buffer and resuspend the cells in 100 μL of flow cytometry buffer. (4) Add hCD45 antibody at a ratio of 1:100 and incubate with shaking at 2-8°C for 0.5-1h. (5) Wash the cells twice with 2 mL of flow cytometry buffer, resuspend the cells with 500 μL of flow cytometry buffer, and perform analysis within 1 h. 2.14 Histopathological examination of mice Making paraffin sections: Dehydration: Place the fixed tissue in a dehydration box and gradually dehydrate it in a dehydration machine. Paraffin embedding: Take out the dehydrated tissue and place it in an embedding frame, pour liquid wax into it, and place it at -20°C to accelerate its solidification. After it is completely solidified, take out the paraffin tissue and trim it. Paraffin sectioning: Use a paraffin slicer to slice the paraffin tissue into thin slices of 4μm thickness. Place the paraffin slices on a spreader with a water temperature of 40°C to slowly unfold the tissue. Then place the tissue on a slide and put it in an oven to dry. After drying, store it at room temperature. HE staining: Dewaxing: The dewaxing process is to soak in xylene solution for 20min, xylene solution for 20min, anhydrous ethanol for 20min, 90% ethanol solution for 2-3min, 80% ethanol for 2-3min, and 70% ethanol for 2-3min. Staining: Place the slices in Harris hematoxylin solution for 3-8 minutes, wash with deionized water, differentiate with 1% hydrochloric acid alcohol for a few seconds, rinse with deionized water, soak in 0.6% ammonia water to turn blue, and rinse with deionized water. Then immerse the slices in eosin solution for 1 minute and rinse with deionized water. Dehydration and sealing: After dehydrating the slices, use neutral gum to seal them. Observation: Observe the slices under an optical microscope, save photos and analyze. 2.15 Immunohistochemistry (IHC) After dewaxing, the sections were repaired, peroxidase was blocked, serum was used for blocking, antibodies were incubated, DAB was used for color development, and finally counterstained and dehydrated. After sealing, the sections were observed under a microscope and photographed for record. 2.16 Transcriptome sequencing analysis of the anti-leukemia mechanism of CL-351 (1) Collect Molt-4 cells in the logarithmic growth phase and centrifuge at 1000 rpm for 5 min. Discard the supernatant and adjust the cell density to 1×10 7 Pieces / bottle. (2) Add 2 mL of CL-351 drug solution to the experimental group to a final concentration of 6.00 μM. Add the same volume of medium without drug to the negative control group. Set up 3-5 replicate wells for each concentration and continue culturing in an incubator. (3) After 48 h of culture, collect the cell suspension in a 10 mL EP tube, centrifuge and discard the supernatant, then wash the cells twice with PBS buffer. (4) Add TriZol lysis buffer and repeatedly pipette until fully lysed. (5) Transfer to a -192°C cryotube and store at -80°C. (6) The cell samples were sent to Hangzhou Lianchuan Biotechnology Co., Ltd. for RNA extraction and detection. (7) Total RNA of the cell sample is used as the starting RNA for library construction, and oligo dT magnetic beads are used to specifically bind to the poly(A) tail to separate the mRNA. Then a sequencing library is constructed. After the library is constructed, the concentration is tested, and if it is qualified, Hangzhou Lianchuan Biotechnology Co., Ltd. is commissioned to perform sequencing. (8) After using Cutadapt to filter out unqualified sequences such as sequencing adapters and low-quality sequences in the original data to obtain valid data, Hisat2 was used for reference genome alignment. (9) Obtain the FPKM values of all genes in each sample and calculate the correlation coefficients between samples and groups. The larger the correlation coefficient, the more similar the expression patterns are and the better the repeatability between samples. (10) The sum of up-regulated genes and down-regulated genes between samples or after different treatments of the same sample is the differentially expressed genes. The threshold standard for screening differentially expressed genes is FC>=2 or FC<=0.5 (i.e., the absolute value of log2FC>=1) and q value<0.05 (|log2fc|>=1&q<0.05). (11) GO enrichment analysis was performed on the differentially expressed genes, including three main components: biological process, molecular function and cellular component. When the p value was less than 0.05, it was considered a significantly enriched GO term. KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis was performed on the differentially expressed genes (p value less than 0.05) to determine the metabolic pathways and signal transduction pathways involved in the differentially expressed genes. (12) Western Blot was used to detect the effect of CL-351 on the expression of key proteins in the PI3K / AKT / mTOR pathway. 2.17 Statistical analysis Data are presented as mean ± standard deviation. Graph Pad Prism 9.0 software was used for statistical analysis. One-way ANOVA was used for comparisons between more than two groups, and differences were considered statistically significant when p < 0.05. 3 Experimental results 3.1CL-351 exhibits significant in vitro anti-tumor activity against leukemia, lymphoma, pancreatic cancer, etc. CL-351 showed significant anti-tumor activity against human leukemia cells Jurkat, Molt-4, CCRF-CEM and CEM / C1, lymphoma cells Raji, SU-DHL-4 and Daudi, pancreatic cancer cells Miapaca-2, etc. It also had a certain proliferation inhibition effect on human lung cancer cells A549, gastric cancer cells SGC-7901, liver cancer cells HepG2, breast cancer cells MDA-MB-231, etc. (see Appendix 1-2). Table 1 IC of CL-351 on different tumor cells after 72h 50 (μM) Table 2 IC of CL-351 on different tumor cells after 72h 50 (μM) 3.2 Effect of CL-351 on the cell cycle of tumor cells CL-351 significantly blocked the cell cycle of Jurkat, Molt-4, CCRF-CEM and CEM / C1 cells. As the concentration of CL-351 increased, the proportion of cells in the G0 / G1 phase of the four leukemia cells continued to decrease, and the proportion of cells in the S phase continued to increase. In addition, the proportion of cells in the G2 / M phase of Molt-4 and CCRF-CEM cells also continued to increase (see Appendix Figure 1 , 2 ). Therefore, CL-351 mainly blocks the leukemia cell cycle at the S phase, and has a significant dose-dependency. For Molt-4 and CCRF-CEM cells, CL-351 can not only block the cell cycle at the S phase, but also at the G2 / M phase. 3.3CL-351 promotes tumor cell apoptosis Annexin V-FITC / PI double staining results showed that CL-351 could induce apoptosis of leukemia cells (see Appendix Figure 3 ). Compared with the negative control group, with the increase of CL-351 concentration, the apoptosis rate of Jurkat cells increased from 4.88% to 40.80%, the apoptosis rate of Molt-4 cells increased from 3.06% to 24.04%, the apoptosis rate of CCRF-CEM cells increased from 4.74% to 32.76%, and the apoptosis rate of CEM / C1 cells increased from 1.51% to 28.16%. All four leukemia cells showed a significant upward trend and were dose-dependent. The results of AO / EB double fluorescence staining experiments showed that compared with the negative control group with uniform green fluorescence, the number and intensity of orange-red fluorescence of leukemia cells in each experimental group also increased with the increase of CL-351 concentration, and the number of apoptotic cells gradually increased, which was dose-dependent (see Appendix). Figure 4). Therefore, CL-351 can promote leukemia cell apoptosis in a dose-dependent manner and has a good effect in inhibiting leukemia cell proliferation. 3.4CL-351 regulates the expression of apoptosis-related proteins in tumor cells Compared with the negative control group, with the increase of CL-351 concentration, the protein expression levels of pro-apoptotic proteins Bax and Caspase-9 in Jurkat and Molt-4 cells gradually increased, and the protein expression level of anti-apoptotic protein Bcl-2 gradually decreased, and both were obviously dose-dependent. Therefore, CL-351 can induce apoptosis of Jurkat and Molt-4 cells by regulating apoptosis-related proteins Bax, Bcl-2 and Caspase-9 (see Appendix Figure 5 ). 3.5CL-351 exhibits significant anti-tumor activity in vivo 3.5.1 CL-351 prolongs the survival of leukemia mice In order to explore the therapeutic effect of CL-351 on leukemia, different doses of CL-351 were administered and the survival time of mice in each group was investigated. The results showed that compared with the negative control group, the survival time of mice in the CL-351 administration group was significantly increased, and the survival time of the CL-351 low, medium and high dose groups was extended by 6d, 13d and 21d respectively (see Appendix Figure 6 ). Therefore, the low, medium and high dose groups of CL-351 prolonged the survival time of leukemia mice to varying degrees. In particular, the survival time of the high dose group of CL-351 was twice that of the negative control group. 3.5.2 CL-351 improves blood routine indicators in leukemia mice Increased peripheral blood leukocyte count and neutropenia are clinical manifestations and diagnostic indicators of leukemia patients. In order to explore the therapeutic effect of CL-351 on leukemia, the number of peripheral blood leukocytes and the proportion of neutrophils in each group of mice were examined after administration of different concentrations of CL-351. The results showed that compared with the negative control group, the number of peripheral blood leukocytes in the low, medium and high dose groups of CL-351 was significantly reduced ( Figure 7 Middle B), p<0.001. The proportion of neutrophils in mice in the medium and high dose groups of CL-351 increased significantly ( Figure 7 A), p<0.001 (see Appendix Figure 7 ). Therefore, the low, medium and high dose groups of CL-351 all restored the blood indicators of leukemia mice to varying degrees. 3.5.3 CL-351 inhibits leukemia cell proliferation in vivo In order to study the inhibitory effect of CL-351 on the proliferation of leukemia cells in vivo, the proliferation of Molt-4 cells in bone marrow and whole blood was investigated by gene comparison rate difference analysis of different species, Wright-Giemsa staining and flow cytometry after administration of different concentrations of CL-351. The results of Wright-Giemsa staining showed that the number of Molt-4 cells in the bone marrow and whole blood of leukemia mice treated with low, medium and high doses of CL-351 decreased (see Appendix Figure 8 The results of the analysis of the gene comparison rates of bone marrow and whole blood of different species showed that after the leukemia mice were treated with the high-dose CL-351 group, the gene comparison rates of the reference genomes of the bone marrow and whole blood were significantly decreased after being compared with the human genome database, among which the bone marrow decreased from 85.91% to 74.05%, and the whole blood decreased from 31.89% to 4.11%. The gene comparison rates of the reference genomes of the bone marrow and whole blood were significantly increased after being compared with the mouse genome database, among which the bone marrow increased from 9.76% to 21.50%, and the whole blood increased from 63.18% to 91.14% (see Appendix Figure 8 Flow cytometry results showed that the proportion of leukemia cells in the bone marrow and whole blood of leukemia mice was significantly reduced after treatment with low, medium and high doses of CL-351 (see Appendix Figure 8 D). Therefore, CL-351 has a significant inhibitory effect on the proliferation of Molt-4 cells in vivo, has a good therapeutic effect on leukemia mice, and greatly reduces the occurrence and development of the disease. 3.5.4 CL-351 inhibits leukemia tissue infiltration Significant enlargement of the liver and spleen is a manifestation of leukemia tissue infiltration. In order to study the inhibitory effect of CL-351 on leukemia tissue infiltration, the size and weight of the liver and spleen of each group of mice and the pathological sections of spleen tissue were examined after different doses of CL-351 were given; hCD45 is a common antigen of leukocytes and can reflect the tissue infiltration of leukemia. Therefore, we detected the expression of hCD45 in mouse spleen tissue by IHC method. The results showed that the size and weight of the liver and spleen of mice in the low, medium and high dose groups of CL-351 were significantly reduced compared with the negative control group (see Appendix Fig. 9 The cell debris and necrosis area in spleen tissue cells of low, medium and high dose groups of CL-351 gradually decreased, and no obvious inflammatory changes were observed (see Appendix Fig. 9 C); The expression of hCD45 in spleen tissue of mice in the low, medium and high dose groups of CL-351 was decreased (see Appendix Fig. 9 Therefore, the low, medium, and high dose groups of CL-351 inhibited the infiltration of leukemia tissues to varying degrees, alleviating further deterioration of the disease. 3.6 Study on the anti-tumor mechanism of CL-351 3.6.1 GO enrichment analysis of differentially expressed genes In order to explore the molecular mechanism of CL-351 in inhibiting leukemia, Molt-4 cells were treated with CL-351, and Gene Ontology (GO) enrichment analysis was performed on the differentially expressed genes to investigate and explore the potential molecular mechanism of CL-351 in inhibiting leukemia. According to the number of annotated differentially expressed genes, the entries of BP, CC, and MF were sorted from most to least, and the top 25, top 15, and top 10 entries were selected for plotting (see Appendix Fig.10 ). Among them, signal transduction was the most significantly enriched in biological processes, with a total of 367 differentially expressed genes; cell membrane was the most significantly enriched in cell composition, with a total of 1301 differentially expressed genes; protein binding was the most significantly enriched in molecular function, with a total of 1923 differentially expressed genes. 3.6.2 KEGG enrichment analysis of differentially expressed genes The Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was performed on the above differentially expressed genes to investigate and explore the potential molecular mechanism of CL-351 against leukemia. Among the enriched pathways, the top 20 pathways with the smallest P value (or Q value) were selected to draw a KEGG enrichment bubble diagram (see Appendix Fig.11 ). The pathway with the most significant enrichment was the PI3K / AKT signaling pathway. Therefore, it is speculated that CL-351 may exert its anti-leukemia effect by inhibiting the PI3K / AKT / mTOR signaling pathway. 3.7CL-351 regulates the expression of key proteins in the PI3K / AKT / mTOR pathway of tumor cells In order to explore the mechanism of CL-351 in inhibiting the proliferation of leukemia cells, the Western Blot method was used to investigate the expression of key proteins in the PI3K / AKT / mTOR signaling pathway in Jurkat and Molt-4 cells after treatment with different concentrations of CL-351. The results showed that compared with the negative control group, the expression levels of p-PI3K, p-AKT and p-mTOR proteins in Jurkat and Molt-4 cells in the CL-351 experimental group were significantly downregulated in a dose-dependent manner; while the expression of PI3K and mTOR proteins did not change significantly; the expression level of AKT protein showed an upward trend with the increase of dose (see Appendix Fig.12). Therefore, CL-351 can inhibit the proliferation of leukemia cells by inhibiting the phosphorylation of key proteins in the PI3K / AKT / mTOR signaling pathway.
Claims
1. Use of 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine or a salt thereof having the following molecular structure in the preparation of a drug, characterized in that: It is used to prepare medicines for treating leukemia, lymphoma, pancreatic cancer, lung cancer, gastric cancer, liver cancer or breast cancer.
2. Use of 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine or a salt thereof in the preparation of a drug according to claim 1, characterized in that: It is made into an injection or oral medicine.
3. Use of 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine or a salt thereof in the preparation of a drug according to claim 2, characterized in that: It is made into intravenous small needle injection, large infusion injection or freeze-dried powder injection.
4. Use of 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine or a salt thereof in the preparation of a drug according to claim 2, characterized in that: It is made into tablets, capsules or pills.
5. Use of 1-(4-alkynyl-2-deoxy-2-fluoro-β-D-ribofuranosyl)cytosine or a salt thereof in the preparation of a drug according to claim 4, characterized in that: It can be made into sustained-release preparation or nano preparation.
Citation Information
Cited By
Application of nucleoside analogue CL-351 in preparation of medicine for regulating immune function
CN120037251A
